Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Treprostinil in Symptomatic Primary or Secondary Raynaud's Phenomenon
NCT07112183Phase 4Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of treprostinil in Raynaud's phenomenon (RP), sponsored by Brigham and Women's Hospital. Started Oct 2025; status: recruiting.
02
Drugs
treprostinil
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT07112183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07112183.